Clinical Trials Directory

Trials / Completed

CompletedNCT01734395

A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease

An Observational, Multi-Center Study to Demonstrate That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease

Status
Completed
Phase
Study type
Observational
Enrollment
1,882 (actual)
Sponsor
Janssen Korea, Ltd., Korea · Industry
Sex
All
Age
50 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to demonstrate that the change of attention measure is correlated with the changes of caregiver's burden after treatment with galantamine.

Detailed description

This is an open-label (all people know the identity of the intervention), prospective (in which the participants are first identified and then followed forward as time passes), observational (study in which the investigators/ physicians observe the patients and measure their outcomes), multi-center (study conducted at multiple sites) study. The study mainly consists of 2 phases including, the screening phase (14 days before administration of study medication) and treatment phase (16 weeks). In the treatment phase, patients will receive galantamine 8 mg/day for the first 4 weeks and later on the dose will be increased up to 24mg (if tolerable). Safety evaluations will include assessment of adverse events. The total duration of the study will be 18 weeks.

Conditions

Interventions

TypeNameDescription
DRUGGalantamineThis is an observational study. Galantamine 8 mg/day will be administered for the first 4 weeks and later on the dose will increased up to 24 mg (if tolerable). Galantamine dose will be adjusted according to the investigator's discretion.

Timeline

Start date
2007-03-01
Primary completion
2008-01-01
Completion
2008-01-01
First posted
2012-11-27
Last updated
2013-08-05
Results posted
2013-08-05

Source: ClinicalTrials.gov record NCT01734395. Inclusion in this directory is not an endorsement.